Tags

Type your tag names separated by a space and hit enter

Intracranial administration of vaccinia virus complement control protein in Mo/Hu APPswe PS1dE9 transgenic mice at an early age shows enhanced performance at a later age using a cheese board maze test.
Biogerontology. 2008 Dec; 9(6):405-20.B

Abstract

One of the key pro-inflammatory mediators activated by amyloid protein in neurodegenerative disorders of the brain, such as Alzheimer's disease is the complement system. Vaccinia virus complement control protein secreted by vaccinia virus, commonly known as VCP, was found to inhibit amyloid protein mediated up-regulation of complement system in vitro. In the current research investigation, VCP was administered twice (First dose at 3 weeks and the second dose at 6-7 months) intracranially into the parietal cortical area of Mo/Hu APPswe transgenic mice. At the age of 2 years or more, the same mice were subjected to cued-learning, spatial learning, probe and reverse probe trial paradigms of cheese board maze tasks for cognitive assessment. A significant difference was observed between VCP treated mice and the transgenic controls on days two and three of the cued trials and probe trials. The VCP treated group showed a similar trend as revealed during the spatial learning trial and reverse probe trial. A differential pattern of thioflavine S staining was observed in the VCP treated group. These results suggest that administration of VCP at an early age in transgenic mice may be effective in regulating the progression to the familial form of Alzheimer's disease at a later age.

Authors+Show Affiliations

Division of Medical Virology, Department of Clinical Laboratory Sciences, Faculty of Health Sciences, Institute of Infectious Diseases and Molecular Medicine (IIDMM), University of Cape Town, Anzio Road, Observatory-07925, Cape Town, South Africa.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18679819

Citation

Kulkarni, Amod P., et al. "Intracranial Administration of Vaccinia Virus Complement Control Protein in Mo/Hu APPswe PS1dE9 Transgenic Mice at an Early Age Shows Enhanced Performance at a Later Age Using a Cheese Board Maze Test." Biogerontology, vol. 9, no. 6, 2008, pp. 405-20.
Kulkarni AP, Pillay NS, Kellaway LA, et al. Intracranial administration of vaccinia virus complement control protein in Mo/Hu APPswe PS1dE9 transgenic mice at an early age shows enhanced performance at a later age using a cheese board maze test. Biogerontology. 2008;9(6):405-20.
Kulkarni, A. P., Pillay, N. S., Kellaway, L. A., & Kotwal, G. J. (2008). Intracranial administration of vaccinia virus complement control protein in Mo/Hu APPswe PS1dE9 transgenic mice at an early age shows enhanced performance at a later age using a cheese board maze test. Biogerontology, 9(6), 405-20. https://doi.org/10.1007/s10522-008-9161-7
Kulkarni AP, et al. Intracranial Administration of Vaccinia Virus Complement Control Protein in Mo/Hu APPswe PS1dE9 Transgenic Mice at an Early Age Shows Enhanced Performance at a Later Age Using a Cheese Board Maze Test. Biogerontology. 2008;9(6):405-20. PubMed PMID: 18679819.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Intracranial administration of vaccinia virus complement control protein in Mo/Hu APPswe PS1dE9 transgenic mice at an early age shows enhanced performance at a later age using a cheese board maze test. AU - Kulkarni,Amod P, AU - Pillay,Nirvana S, AU - Kellaway,Lauriston A, AU - Kotwal,Girish J, Y1 - 2008/08/05/ PY - 2008/04/02/received PY - 2008/07/10/accepted PY - 2008/8/6/pubmed PY - 2009/2/3/medline PY - 2008/8/6/entrez SP - 405 EP - 20 JF - Biogerontology JO - Biogerontology VL - 9 IS - 6 N2 - One of the key pro-inflammatory mediators activated by amyloid protein in neurodegenerative disorders of the brain, such as Alzheimer's disease is the complement system. Vaccinia virus complement control protein secreted by vaccinia virus, commonly known as VCP, was found to inhibit amyloid protein mediated up-regulation of complement system in vitro. In the current research investigation, VCP was administered twice (First dose at 3 weeks and the second dose at 6-7 months) intracranially into the parietal cortical area of Mo/Hu APPswe transgenic mice. At the age of 2 years or more, the same mice were subjected to cued-learning, spatial learning, probe and reverse probe trial paradigms of cheese board maze tasks for cognitive assessment. A significant difference was observed between VCP treated mice and the transgenic controls on days two and three of the cued trials and probe trials. The VCP treated group showed a similar trend as revealed during the spatial learning trial and reverse probe trial. A differential pattern of thioflavine S staining was observed in the VCP treated group. These results suggest that administration of VCP at an early age in transgenic mice may be effective in regulating the progression to the familial form of Alzheimer's disease at a later age. SN - 1389-5729 UR - https://www.unboundmedicine.com/medline/citation/18679819/Intracranial_administration_of_vaccinia_virus_complement_control_protein_in_Mo/Hu_APPswe_PS1dE9_transgenic_mice_at_an_early_age_shows_enhanced_performance_at_a_later_age_using_a_cheese_board_maze_test_ L2 - https://doi.org/10.1007/s10522-008-9161-7 DB - PRIME DP - Unbound Medicine ER -